DoD Gulf War Illness Research Program
Clinical Evaluation Award
Amount of funding: Direct costs budgeted will not exceed $1,500,000. If applying under the Biorepository Contribution Option, direct costs will not exceed $1,520,000. If applying under the Clinical Consortium Collaboration Option, direct costs will not exceed $1,700,000.
Purpose: The FY21 GWIRP Clinical Evaluation Award supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population. The Clinical Evaluation Award targets the Verification phase of the research pipeline. Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, phase 1-2a) are encouraged under this funding opportunity. Clinical trials may be designed to evaluate pharmacologic agents (drugs or biologics), devices, clinical guidance or other approaches, and technologies supported by strong objective evidence in the GWI field. While studies of treatments repurposed from other disorders sharing GWI symptomatology will be considered (with appropriate rationale), the FY21 GWIRP encourages studies that translate qualified results from the GWI research community.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be the PI.
Not eligible: Instructors, Clinical Instructors, Academic Staff-Research (i.e., research associates), Postdocs, and Clinical fellows are not eligible.
Pre-application/Letter of intent (required) deadline: May 7, 2021 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) deadline: August 12, 2021
Full proposal deadline: August 19, 2021via grants.gov